Astellas pulls lawsuit over price negotiations as Xtandi sidesteps first list of 10 drugs
Astellas on Wednesday voluntarily dismissed its lawsuit against the Biden administration’s HHS after its prostate cancer drug Xtandi (enzalutamide) was not included in the initial list of drugs that will face price negotiations in 2026.
Astellas said in a statement on Wednesday afternoon:
[The decision] does not change our fundamental belief that in its current form, the Medicare Drug Price Negotiation Program (Program) created by the IRA is bad policy and unconstitutional. The price-setting policies in the Program will disrupt the competitive marketplace for prescription drugs in the U.S., disincentivize critical research and development efforts for hard-to-treat conditions, and diminish the availability of new medicines for patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.